Cenerimod

About Ono Pharmaceutical

Ono Pharmaceutical's mission is to address unmet medical needs through the discovery and development of first-in-class and best-in-class therapeutic agents. The company has achieved global recognition primarily through its strategic alliance with Bristol Myers Squibb on the blockbuster PD-1 inhibitor Opdivo (nivolumab), which established its strong foothold in immuno-oncology. Its strategy centers on sustained internal R&D investment, complemented by strategic partnerships and in-licensing to expand its pipeline and global commercial reach. Ono is now executing a multi-faceted growth plan to diversify its portfolio beyond Opdivo and solidify its position as a global specialty pharma leader.

About Idorsia

Idorsia's mission is to discover, develop, and commercialize innovative medicines, building on a legacy of scientific excellence from its Actelion origins. Its key achievement is the global commercialization of QUVIVIQ (daridorexant), a dual orexin receptor antagonist for insomnia, alongside the recent approval of TRYVIO/JERAYGO (aprocitentan) for resistant hypertension. The company's strategy is centered on unlocking the full value of its commercial assets, expanding strategic partnerships, advancing a prioritized pipeline, and maintaining financial discipline, all supported by a highly skilled team of approximately 500 employees.

Therapeutic Areas

Other Systemic Lupus Erythematosus (SLE) Drugs